Key Events This Week
07 Sep: New 52-week and all-time high at Rs.133.75
08-11 Sep: Price consolidation at Rs.133.75 amid declining Sensex
11 Sep: Week closes at Rs.133.75 (+0.98%) vs Sensex -1.68%
07 September: Parmax Pharma Hits New 52-Week and All-Time High
On Monday, 07 Sep 2026, Parmax Pharma Ltd surged to Rs.133.75, marking both a new 52-week and all-time high. This price level represents a remarkable one-year gain of 274.02% from its 52-week low of Rs.22.60, and an even more striking year-to-date increase of 295.36%. The stock’s performance on this day was particularly notable as it outperformed the Pharmaceuticals & Biotechnology sector by 0.63%, while the Sensex declined by 0.40% to close at 36,218.97.
The stock opened and traded steadily at Rs.133.75 throughout the session, indicating strong demand and price support at this level. Technical indicators remain bullish, with the stock trading above all key moving averages (5, 20, 50, 100, and 200 days). Weekly and monthly MACD, Bollinger Bands, KST, and Dow Theory indicators all signal sustained upward momentum, although the monthly RSI suggests some caution.
Despite the impressive price action, Parmax Pharma remains a micro-cap entity with relatively low trading volumes and intermittent liquidity, as evidenced by the stock not trading on four of the last twenty days. The company’s Mojo Score stands at 46.0 with a 'Sell' grade, upgraded from 'Strong Sell' on 10 Aug 2026, reflecting some improvement in fundamentals but still signalling caution.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
08 to 11 September: Price Consolidation Amid Market Weakness
From 08 Sep through 11 Sep 2026, Parmax Pharma’s share price remained steady at Rs.133.75, showing no daily change despite the Sensex’s persistent decline. The benchmark index fell cumulatively by 1.68% over the week, closing at 35,773.24 on 11 Sep. This divergence highlights Parmax Pharma’s relative resilience in a broadly bearish market environment.
The stock’s stable price during these sessions suggests consolidation at the new high level, with investors possibly digesting the recent gains. Trading volumes remained consistent at 2,018 shares daily, reflecting the micro-cap nature of the stock and limited liquidity. The lack of price movement also indicates a balance between buying and selling pressures amid cautious market sentiment.
Technical momentum remains intact, with the stock maintaining its position above all major moving averages. However, the absence of further upward movement may reflect the cautious stance of market participants given the company’s mixed fundamental profile.
Holding Parmax Pharma Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Weekly Price Performance: Parmax Pharma vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-09-07 | Rs.133.75 | +0.98% | 36,218.97 | -0.46% |
| 2026-09-08 | Rs.133.75 | +0.00% | 36,144.32 | -0.21% |
| 2026-09-09 | Rs.133.75 | +0.00% | 35,921.77 | -0.62% |
| 2026-09-10 | Rs.133.75 | +0.00% | 35,912.77 | -0.03% |
| 2026-09-11 | Rs.133.75 | +0.00% | 35,773.24 | -0.39% |
Key Takeaways from the Week
Positive Signals: Parmax Pharma’s ability to hit a new 52-week and all-time high at Rs.133.75 amidst a declining Sensex highlights its strong price momentum and relative outperformance. The stock’s technical indicators remain bullish, trading above all major moving averages, and delivery volumes have shown positive trends in recent months. The upgrade in Mojo Grade from Strong Sell to Sell suggests some improvement in underlying fundamentals.
Cautionary Notes: Despite the price strength, Parmax Pharma remains a micro-cap with low liquidity and intermittent trading activity. The company’s financials reflect ongoing challenges, including loss-making status, negative valuation multiples, and declining sales and EBIT over five years. The monthly RSI’s bearish signal and reliance on non-operating income for profits warrant careful monitoring. The Mojo Score of 46.0 and Sell rating indicate that risks remain significant.
Conclusion: A Week of Milestones Amid Mixed Fundamentals
Parmax Pharma Ltd’s week was defined by the achievement of new 52-week and all-time highs, underscoring a strong price rally that contrasts with the broader market’s weakness. The stock’s 0.98% weekly gain against the Sensex’s 1.68% decline reflects its resilience and technical strength. However, the company’s fundamental profile remains mixed, with ongoing losses and valuation challenges tempering enthusiasm.
Investors observing Parmax Pharma should weigh its impressive price momentum and recent financial improvements against the inherent risks of its micro-cap status and fundamental uncertainties. The stock’s performance this week adds a noteworthy chapter to its market journey, but caution remains advisable given the complex backdrop.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
